Segment, Geographical and Other Revenue Information (Tables)

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Schedule of segment reporting

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):

	Three months ended March 31, 2020						Three months ended March 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	5,100	$	—	$	5,100	$	7,988	$	—	$	7,988
Research and development revenue	5,774		3,796		9,570		2,099		5,496		7,595
Total revenues	10,874		3,796		14,670		10,087		5,496		15,583
Costs and operating expenses:
Cost of product revenue	2,541		—		2,541		4,391		—		4,391
Research and development(1)	5,696		4,925		10,621		4,442		3,317		7,759
Selling, general and administrative(1)	2,345		591		2,936		2,101		517		2,618
Total segment costs and operating expenses	10,582		5,516		16,098		10,934		3,834		14,768
Income (loss) from operations	$	292	$	(1,720)	(1,428)		$	(847)	$	1,662	815
Corporate costs (2)					(5,727)						(5,575)
Depreciation and amortization					(492)						(373)
Loss before income taxes					$	(7,647)					$	(5,133)

⁽¹⁾ Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases.

⁽²⁾ Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in loss from operations (in thousands):

	Three months ended March 31,
	2020								2019
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	756	$	241	$	1,172	$	2,169	$	636	$	141	$	1,286	$	2,063

Schedule of customers that contributed 10% or more of total accounts receivable

Customers that each accounted for 10% or more of our total revenues were as follows:

	Three Months Ended March 31,
	2020		2019
Customer A	24	%	41	%
Customer B	19	%	—	%
Customer C	15	%	—	%
Customer D	11	%	35	%

Customers that each accounted for 10% or more of accounts receivable had balances as of the periods presented as follows:

	Percentage of Accounts Receivables as of
	March 31, 2020		December 31, 2019
Customer A	47	%	38	%
Customer D	—	%	10	%

* Percentage was less than 10%

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):

	Three Months Ended March 31,
	2020		2019
Revenues
Americas	$	5,225	$	2,838
EMEA	5,971		7,726
APAC	3,474		5,019
Total revenues	$	14,670	$	15,583

Schedule of long-lived assets by geographical area

Identifiable long-lived assets by location was as follows (in thousands):

Long-lived assets	March 31, 2020		December 31, 2019
United States	$	6,647	$	6,282

Schedule of intangible assets and goodwill

Identifiable goodwill was as follows (in thousands):

	March 31, 2020						December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241	$	2,463	$	778	$	3,241